Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease.

Erwin DreesenSophie BerendsDavid LaharieGeert D'HaensSeverine VermeireAnn GilsRon Mathôt

Published in: British journal of clinical pharmacology (2020)

Model-informed infliximab dose optimisation towards a predefined fCal concentration (while accounting for PK and PD variability) may improve effectiveness of infliximab therapy.

Keyphrases

ulcerative colitis
disease activity
randomized controlled trial
systematic review
rheumatoid arthritis
stem cells
systemic lupus erythematosus
mesenchymal stem cells
cell therapy